ICCC Q2 2020 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena

ICCCImmuCell Corporation

$60M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+9.4% YoY

Gross Profit

$1M43.3% margin

Operating Income

-$691,269-23.3% margin

Net Income

-$765,793-25.8% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-39.6%

Cash Flow

Operating Cash Flow

$969,204

Free Cash Flow

-$93,385

Stock-Based Comp.

$56,634

Balance Sheet

Total Assets

$41M

Total Liabilities

$12M

Stockholders' Equity

$28M

Cash & Equivalents

$6M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$3M	+9.4%
Gross Profit	$1M	$1M	+2.7%
Operating Income	-$691,269	-$547,000	-26.4%
Net Income	-$765,793	-$627,000	-22.1%